C1-GBM displayed elevated immune microenvironment scores and immunological activity, consistent with an immune-inflamed (“hot”) phenotype, and showed enrichment patterns suggestive of potential responsiveness to anti-PD-1/PD-L1 immunotherapy. The gene discussed is CD274; the disease is glioblastoma.